INVA Innoviva, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1080014 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY12.8%
TTM net income YoY51.9%
TTM EPS YoY41.6%
Revenue 3-yr CAGR14.7%
Net income 3-yr CAGR57.1%
Margins
Gross margin74.5%
Operating margin38.8%
Net margin44.1%
FCF margin41.6%
EBITDA margin—
Returns
ROE18.0%
ROA13.0%
ROIC (approx.)18.3%
Asset turnover0.30x
Leverage & solvency
Liabilities / assets26.0%
Debt / equity0.23x
Current ratio15.44x
Interest coverage8.64x
Cash quality & payout
Operating cash flow / net income0.95x
Accruals ratio0.7%
Payout ratio—
Capex / revenue0.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY2025*2025-12-31 | FY2024*2024-12-31 | FY2023*2023-12-31 | FY2022*2022-12-31 | FY2021*2021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $411.33M | $358.71M | $310.46M | $331.34M | $391.87M |
| Gross profit | $307.67M | $296.21M | $246.04M | — | — |
| R&D expense | $30.60M | $13.65M | $33.92M | $41.43M | $576,000 |
| SG&A expense | $113.32M | $115.69M | $98.23M | $63.54M | $16.19M |
| Operating income | $163.75M | $166.87M | $113.89M | — | $375.10M |
| Interest expense | $16.70M | $22.21M | $19.16M | $15.79M | $19.07M |
| Pretax income | $326.86M | $37.39M | $194.10M | $286.95M | $445.28M |
| Income tax | $55.70M | $14.00M | $14.38M | $66.69M | $76.44M |
| Net income | $271.17M | $23.39M | $179.72M | $213.92M | $265.85M |
| EBITDA | — | — | — | — | $388.94M |
| EPS (basic) | 4.02 | 0.37 | 2.75 | 3.07 | 3.24 |
| EPS (diluted) | 3.30 | 0.36 | 2.20 | 2.37 | 2.87 |
| Weighted avg. shares (diluted) | 84.76M | 74.19M | 86.88M | 95.25M | 94.31M |
| Balance sheet | |||||
| Cash & equivalents | $550.94M | $304.96M | $193.51M | $291.05M | $201.53M |
| Short-term investments | — | — | — | — | $0 |
| Inventory | $39.17M | $33.73M | $40.74M | $55.90M | $0 |
| Current assets | $727.51M | $554.31M | $344.22M | $443.51M | $313.67M |
| PP&E, net | $1.55M | $514,000 | $483,000 | $170,000 | $12,000 |
| Goodwill | $17.91M | $17.91M | $17.91M | $26.71M | $0 |
| Intangibles | $182.16M | $208.43M | $230.34M | $252.92M | $0 |
| Total assets | $1.64B | $1.30B | $1.24B | $1.23B | $926.39M |
| Current liabilities | $49.70M | $236.08M | $38.13M | $134.97M | $5.81M |
| Short-term debt | $0 | $192.03M | $0 | $96.19M | $0 |
| Long-term debt | $257.73M | $256.32M | $446.23M | $444.18M | $394.65M |
| Total debt | $257.73M | $448.34M | $446.23M | $540.37M | $394.65M |
| Total liabilities | $462.32M | $609.90M | $568.55M | $665.71M | $400.46M |
| Shareholders' equity | $1.17B | $691.16M | $674.96M | $565.79M | $414.74M |
| Net debt | -$293.21M | $143.38M | $252.72M | $249.32M | $193.13M |
| Shares outstanding | 74.64M | 62.66M | 63.31M | 69.19M | 69.57M |
| Cash flow statement | |||||
| Operating cash flow | $196.93M | $188.69M | $141.06M | $201.73M | $363.81M |
| Capital expenditure | $1.13M | $270,000 | $411,000 | $67,000 | $0 |
| Free cash flow | $195.80M | $188.42M | $140.65M | $201.66M | $363.81M |
| Investing cash flow | $40.50M | -$63.79M | -$66.76M | -$56.63M | $43.72M |
| Financing cash flow | $8.55M | -$13.45M | -$171.84M | -$55.57M | -$452.50M |
| Depreciation & amortization | — | — | — | — | $13.83M |
| Stock-based compensation | $9.45M | $6.37M | $5.84M | $7.35M | $2.02M |
| Dividends paid | — | — | — | — | $0 |
| Share buybacks | $4.53M | $14.78M | $75.73M | $8.50M | $394.15M |
Free plan shows the latest 5 periods; Pro shows all 17 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.